Pregled bibliografske jedinice broj: 1252261
Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies
Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies // Expert Review of Neurotherapeutics, 21 (2021), 11; 1275-1282 doi:10.1080/14737175.2021.1885374 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1252261 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Managing CLN2 disease: a treatable
neurodegenerative condition among other treatable
early childhood epilepsies
Autori
Mazurkiewicz-Bełdzińska, Maria ; del Toro, Mireia ; Haliloğlu, Göknur ; Huidekoper, Hidde H. ; Kravljanac, Ružica ; Mühlhausen, Chris ; Andersen, Brian Nauheimer ; Prpić, Igor ; Striano, Pasquale ; Auvin, Stéphane
Izvornik
Expert Review of Neurotherapeutics (1473-7175) 21
(2021), 11;
1275-1282
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
CLN2 disease ; diagnosis ; epilepsy ; language ; late infantile ; seizures
Sažetak
Introduction: Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric neurodegenerative condition, which is usually fatal by mid-adolescence. Seizures are one of the most common early symptoms of CLN2 disease, but patients often experience language deficits, movement disorders, and behavioral problems. Diagnosis of CLN2 disease is challenging (particularly when differentiating between early- onset developmental, metabolic, or epileptic syndromes), and diagnostic delays often overlap with rapid disease progression. An enzyme replacement therapy (cerliponase alfa) is now available, adding CLN2 disease to the list of potentially treatable disorders requiring a prompt diagnosis. Areas covered: Although advances in enzymatic activity testing and genetic testing have facilitated diagnoses of CLN2 disease, our review highlights the presenting symptoms that are vital in directing clinicians to perform appropriate tests or seek expert opinion. We also describe common diagnostic challenges and some potential misdiagnoses that may occur during differential diagnosis. Expert opinion: An awareness of CLN2 disease as a potentially treatable disorder and increased understanding of the key presenting symptoms can support selection of appropriate tests and prompt diagnosis. The available enzyme replacement therapy heralds an even greater imperative for early diagnosis, and for clinicians to direct patients to appropriate diagnostic pathways.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Profili:
Igor Prpić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE